StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a research report sent to investors on Tuesday. The firm issued a buy rating on the stock.
A number of other equities research analysts have also recently issued reports on the stock. Laidlaw cut shares of MEI Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Brookline Capital Management downgraded shares of MEI Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, July 22nd. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.00.
Check Out Our Latest Research Report on MEI Pharma
MEI Pharma Price Performance
MEI Pharma (NASDAQ:MEIP – Get Free Report) last announced its earnings results on Thursday, September 19th. The company reported ($1.13) EPS for the quarter, topping the consensus estimate of ($1.48) by $0.35. As a group, equities analysts anticipate that MEI Pharma will post -5.1 earnings per share for the current fiscal year.
Institutional Trading of MEI Pharma
An institutional investor recently raised its position in MEI Pharma stock. National Bank of Canada FI boosted its stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) by 43.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. National Bank of Canada FI owned about 0.50% of MEI Pharma worth $94,000 at the end of the most recent reporting period. 52.38% of the stock is currently owned by hedge funds and other institutional investors.
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Articles
- Five stocks we like better than MEI Pharma
- Stock Analyst Ratings and Canadian Analyst Ratings
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Canadian Penny Stocks: Can They Make You Rich?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What is Forex and How Does it Work?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.